What this work is about, in plain words
An abstract on a mouse model of intestinal inflammation: according to the authors, Leptolyngbya cf. ectocarpi biomass reduced signs of inflammation roughly as much as the comparison drugs.
Inflammatory bowel diseases are studied in mice: inflammation is induced with dextran sulfate sodium, and researchers look at what alleviates it. The authors tested how the marine cyanobacterium Leptolyngbya cf. ectocarpi affects this model.
The cyanobacterium was grown under high light. Female CD-1 mice received dextran sulfate sodium into the stomach for five days. Some mice received a suspension or extract of the cyanobacterium 7 days before, others 30 minutes after; the drugs cyclophosphamide and prednisolone were used for comparison. White blood cells, the total clinical sign score (weight loss, stool character and others), blood cytokines and the properties of intestinal cells were assessed.
According to the authors, in untreated mice the total score reached 10, while in the groups given the cyanobacterium it was 2–4, against 5 for the comparison drugs. The cyanobacterium reduced white blood cells (except when the extract was given beforehand), reduced the inflammatory cytokines IL-1β and TNFα and increased the anti-inflammatory IL-10.
Limitations. A brief abstract without group sizes or detailed statistics; comparison with drugs does not mean equal efficacy. The data apparently overlap with the article in the Siberian Scientific Medical Journal (2026). A study in mice; this is not a basis for conclusions about treating Crohn's disease or ulcerative colitis in people.